Stifel lowered the firm’s price target on Vitalhub (VHIBF) to C$11 from C$13.50 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VHIBF:
- Vitalhub price target lowered to C$11 from C$12 at RBC Capital
- VHI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- VitalHub’s Novari Health Expands AI-Driven Referral Management at Niagara Health
- Vitalhub announces Novari Health AI-enhanced referral management deployment
- VitalHub Sets March Dates to Unveil Q4 2025 Results and Host Investor Call